Chemerin serum levels at baseline were not related to sex, age, BMI, lipid profile (TC, HDL, LDL, TG, Apo A-I, Apo B, Lp(a)), systolic or diastolic blood pressure, cardiovascular events in the medical history, diabetes or the use of statins and anti-hypertensive drugs, or was the change in chemerin levels 16 weeks after initiation of adalimumab treatment related to the change in lipid profile. This evidence concerns the gene RARRES2 and diabetes mellitus.